Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

Area of Science:

• Oncology
• Immunology
• Pulmonology

Background:

• Advanced non-small cell lung cancer (NSCLC) treatment has evolved significantly.
• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a key therapeutic strategy.
• ICIs targeting PD-1, PDL-1, and CTLA-4 have transformed care for advanced NSCLC lacking driver mutations.

Purpose of the Study:

• To provide a comprehensive overview of current immunotherapy treatments for advanced NSCLC.
• To discuss the evolving role of ICIs from second-line to first-line therapy.
• To explore novel combinations and future directions in NSCLC immunotherapy.

Main Methods:

• Comprehensive literature review of immunotherapy in advanced NSCLC.
• Analysis of data regarding PD-1, PDL-1, and CTLA-4 inhibitors.
• Evaluation of combination therapies including chemotherapy, VEGF inhibitors, and radiotherapy.

Main Results:

• ICIs have significantly improved outcomes in advanced NSCLC lacking driver mutations since 2015.
• New agents like cemiplimab and earlier ICI use enhance treatment prospects.
• Combination therapy (chemotherapy, VEGF inhibitor, immunotherapy) improves survival regardless of PD-L1 status in low-expressing tumors.
• Radiotherapy combined with immunotherapy shows promising results.

Conclusions:

• Immunotherapy has fundamentally changed the treatment landscape for advanced NSCLC.
• Combination strategies offer improved survival benefits for a broader patient population.
• Ongoing research and emerging therapies provide optimism for future NSCLC treatment.
• Safety profiles and resistance mechanisms of ICIs require continued attention.